Keywords: astrazeneca, stroke, drug, fails, late-stage, trials, terminated
AstraZeneca stroke drug fails in late-stage trials
Article | 16 November 2000
AstraZeneca has terminated development of Zendra (clomethiazole) inthe treatment of stroke, after data showed no efficacy in the 1,200-patient Class-1 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
